BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26451293)

  • 1. Progressive loss of anti-HER2 CD4
    Datta J; Rosemblit C; Berk E; Showalter L; Namjoshi P; Mick R; Lee KP; Brod AM; Yang RL; Kelz RR; Fitzpatrick E; Hoyt C; Feldman MD; Zhang PJ; Xu S; Koski GK; Czerniecki BJ
    Oncoimmunology; 2015 Oct; 4(10):e1022301. PubMed ID: 26451293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
    Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
    Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
    Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
    JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.
    Fracol M; Datta J; Lowenfeld L; Xu S; Zhang PJ; Fisher CS; Czerniecki BJ
    Ann Surg Oncol; 2017 Feb; 24(2):407-417. PubMed ID: 27663569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
    Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
    Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.
    Nocera NF; Lee MC; De La Cruz LM; Rosemblit C; Czerniecki BJ
    Front Pharmacol; 2016; 7():356. PubMed ID: 27766079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncodriver inhibition and CD4
    Rosemblit C; Datta J; Lowenfeld L; Xu S; Basu A; Kodumudi K; Wiener D; Czerniecki BJ
    Oncotarget; 2018 May; 9(33):23058-23077. PubMed ID: 29796172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER
    Lowenfeld L; Zaheer S; Oechsle C; Fracol M; Datta J; Xu S; Fitzpatrick E; Roses RE; Fisher CS; McDonald ES; Zhang PJ; DeMichele A; Mick R; Koski GK; Czerniecki BJ
    Oncoimmunology; 2017; 6(9):e1207032. PubMed ID: 28932627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER2 CD4
    De La Cruz LM; McDonald ES; Mick R; Datta J; Nocera NF; Xu S; Fisher CS; Czerniecki BJ
    Ann Surg Oncol; 2017 Apr; 24(4):1057-1063. PubMed ID: 27826664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2
    Lowenfeld L; Mick R; Datta J; Xu S; Fitzpatrick E; Fisher CS; Fox KR; DeMichele A; Zhang PJ; Weinstein SP; Roses RE; Czerniecki BJ
    Clin Cancer Res; 2017 Jun; 23(12):2961-2971. PubMed ID: 27965306
    [No Abstract]   [Full Text] [Related]  

  • 11. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
    De La Cruz LM; Nocera NF; Czerniecki BJ
    Immunotherapy; 2016 Oct; 8(10):1219-32. PubMed ID: 27605070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
    Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
    J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4
    Lowenfeld L; Xu S; Czerniecki BJ
    Oncoimmunology; 2019; 8(10):e1078062. PubMed ID: 31646065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.
    Pinto RA; Arredondo SM; Bono MR; Gaggero AA; Díaz PV
    Pediatrics; 2006 May; 117(5):e878-86. PubMed ID: 16618789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
    Jia Y; Kodumudi KN; Ramamoorthi G; Basu A; Snyder C; Wiener D; Pilon-Thomas S; Grover P; Zhang H; Greene MI; Mo Q; Tong Z; Chen YZ; Costa RLB; Han H; Lee C; Soliman H; Conejo-Garcia JR; Koski G; Czerniecki BJ
    Mol Ther; 2021 Apr; 29(4):1541-1556. PubMed ID: 33412308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy.
    Heinzel FP; Rerko RM
    J Exp Med; 1999 Jun; 189(12):1895-906. PubMed ID: 10377185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.